NCT05572645已完成不适用
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 333
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
详细描述
This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in patients with HER2-positive metastatic breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.
- •Patients received Pyrotinib(320-400 mg, po, qd) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) or Pertuzumab(840mg q3w, and then 420 mg q3w) plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w) for at least one cycle, starting from Jan 2018 to Sep
- •Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.
排除标准
- •Incomplete medical history
研究组 & 干预措施
PyroH
treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
干预措施: Pyrotinib Plus Trastuzumab (Drug)
PertH
treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
干预措施: Pertuzumab Plus Trastuzumab (Drug)
结局指标
主要结局
PFS
时间窗: 6 weeks
Progression free survival
次要结局
- Adverse Events(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical StudyBreast CancerNCT06770296The First Affiliated Hospital with Nanjing Medical University200
Unknown
不适用
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.Colorectal CancerNCT03843749Shanghai Changzheng Hospital30
进行中（未招募）
2 期
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast CancerBreast Cancer InvasiveNCT04398914Shanghai Jiao Tong University School of Medicine216
Unknown
2 期
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerBreast Cancer FemaleHER2-positive Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastBreast DiseasesHormone Receptor Positive TumorMetastatic Breast CancerNCT04088110Fuzhou General Hospital77
招募中
2 期
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038HER2-positive Breast CancerNCT05429294First Affiliated Hospital Xi'an Jiaotong University209